Researchers at UNMC have discovered that patients with diffuse large B-cell lymphoma don't respond well to the standard drug therapy used to treat this type of cancer if they have high levels of a gene called STAT3. "These results are significant in that it gives oncologists a better understanding of the best way to personalize medical treatment for these patients and offer them hope for more positive outcomes," said Kai Fu, M.D., associate professor in the department of pathology and microbiology. Read more here.
Study mentioned: Huang X, et al. Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol. 2013 Nov 12. [Epub ahead of print] PMID: 24220556
No comments:
Post a Comment